MEDBOT-B (02252) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of RMB 176 million, representing a 77% year-on-year increase. During the period, the adjusted net loss was RMB 97.108 million, down 55.5% compared to the same period last year. Loss attributable to equity shareholders of the company was RMB 113 million, decreasing 59.1% year-on-year, with loss per share of RMB 0.11.

According to the announcement, the revenue growth was primarily driven by the rapid expansion of commercialization across multiple products, particularly with overseas markets achieving a significant 189% year-on-year growth. The company's core product, the Toumai laparoscopic surgery robot, continued to maintain strong growth momentum, with overseas markets serving as the core engine for revenue growth.

The Honghu orthopedic surgery robot fully leveraged MicroPort's mature sales network in both domestic and international markets, achieving rapid coverage and penetration in core regions while independently developing emerging regions, creating a "dual-drive" model for steady growth. Following its market launch, the R-ONE vascular intervention surgery robot has gained market recognition with steadily rising demand.